Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended September 30, 2009. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on November 30, 2009 to stockholders of record on November 9, 2009.
Operating Results Attributable to Stockholders
For the quarter ended September 30, 2009:
- Allergan reported $0.58 diluted earnings per share attributable to stockholders compared to $0.54 diluted earnings per share attributable to stockholders reported for the third quarter of 2008.
- Allergan’s non-GAAP diluted earnings per share attributable to stockholders were $0.70 in the third quarter of 2009, compared to non-GAAP diluted earnings per share attributable to stockholders of $0.65 in the third quarter of 2008, a 7.7 percent increase.
Product Sales
For the quarter ended September 30, 2009:
- Allergan’s total product net sales were $1,127.8 million. Total product net sales increased 4.2 percent compared to total product net sales in the third quarter of 2008. On a constant currency basis, total product net sales increased 7.0 percent compared to total product net sales in the third quarter of 2008.
- Total specialty pharmaceuticals net sales increased 7.8 percent, or 10.7 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the third quarter of 2008.
- Total medical devices net sales decreased 10.6 percent, or 8.3 percent on a constant currency basis, compared to total medical devices net sales in the third quarter of 2008.
“We are pleased with our continued operational performance during the third quarter as our businesses are performing better than was expected at the beginning of 2009,” said David E.I. Pyott, Allergan’s Chairman of the Board and Chief Executive Officer. “With this strength in our businesses, we made the strategic decision to invest in increased Direct to Consumer advertising programs in the U.S. as we anticipate recovery from the recession. We are also pleased that we filed, with the U.S. Food and Drug Administration (FDA), BOTOX® (onabotulinumtoxinA) for chronic migraine as well as for upper limb spasticity.”
Product and Pipeline Update
During the third quarter of 2009: